Morgan Stanley
LKFT

Morgan Stanley’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

Morgan Stanley’s Portfolio LKFT Stock Details LKFT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$799K Sell
26,619
-41,666
-61% -$1.38M ﹤0.01% 5260
2025
Q4 		$2.23M Buy
68,285
+4,222
+7% +$136K ﹤0.01% 4735
2025
Q3 		$2.22M Sell
64,063
-2,101
-3% -$67.2K ﹤0.01% 4712
2025
Q2 		$1.85M Buy
66,164
+40,757
+160% +$1.09M ﹤0.01% 4749
2025
Q1 		$638K Sell
25,407
-118,730
-82% -$3M ﹤0.01% 5222
2024
Q4 		$3.96M Buy
144,137
+59,782
+71% +$1.67M ﹤0.01% 4188
2024
Q3 		$2.43M Sell
84,355
-29,374
-26% -$800K ﹤0.01% 4505
2024
Q2 		$2.82M Buy
113,729
+90,067
+381% +$2.56M ﹤0.01% 4333
2024
Q1 		$762K Sell
23,662
-198,998
-89% -$7.4M ﹤0.01% 5114
2023
Q4 		$9.05M Buy
222,660
+199,310
+854% +$7.33M ﹤0.01% 3999
2023
Q3 		$807K Sell
23,350
-11,214
-32% -$437K ﹤0.01% 4921
2023
Q2 		$1.41M Sell
34,564
-72,427
-68% -$2.95M ﹤0.01% 4624
2023
Q1 		$4.13M Sell
106,991
-13,672
-11% -$562K ﹤0.01% 3935
2022
Q4 		$5.36M Sell
120,663
-59,024
-33% -$2.48M ﹤0.01% 3695
2022
Q3 		$7.66M Sell
179,687
-8,989
-5% -$461K ﹤0.01% 3248
2022
Q2 		$10.5M Buy
188,676
+37,662
+25% +$2.23M ﹤0.01% 3019
2022
Q1 		$9.37M Buy
151,014
+49,639
+49% +$3.04M ﹤0.01% 2974
2021
Q4 		$5.59M Sell
101,375
-40,951
-29% -$2.14M ﹤0.01% 3605
2021
Q3 		$7.49M Sell
142,326
-34,053
-19% -$2.02M ﹤0.01% 3265
2021
Q2 		$12.2M Buy
176,379
+10,317
+6% +$787K ﹤0.01% 2766
2021
Q1 		$12.8M Buy
166,062
+38,405
+30% +$3.54M ﹤0.01% 2396
2020
Q4 		$12.6M Buy
127,657
+77,366
+154% +$9.46M ﹤0.01% 2274
2020
Q3 		$7.14M Sell
50,291
-42,765
-46% -$7.13M ﹤0.01% 2355
2020
Q2 		$18.4M Sell
93,056
-28,125
-23% -$5.82M ﹤0.01% 1474
2020
Q1 		$23.7M Buy
121,181
+49,053
+68% +$10.6M 0.01% 1168
2019
Q4 		$14.9M Sell
72,128
-30,349
-30% -$5.61M ﹤0.01% 1951
2019
Q3 		$15.6M Buy
102,477
+36,640
+56% +$6M ﹤0.01% 1688
2019
Q2 		$8.49M Buy
65,837
+1,111
+2% +$132K ﹤0.01% 2340
2019
Q1 		$7.62M Sell
64,726
-6,705
-9% -$676K ﹤0.01% 2307
2018
Q4 		$6.55M Sell
71,431
-7,888
-10% -$800K ﹤0.01% 2570
2018
Q3 		$8.92M Buy
79,319
+7,752
+11% +$819K ﹤0.01% 2529
2018
Q2 		$6.6M Buy
71,567
+15,237
+27% +$1.48M ﹤0.01% 2839
2018
Q1 		$5.62M Sell
56,330
-27,803
-33% -$3M ﹤0.01% 2901
2017
Q4 		$7.89M Buy
84,133
+19,859
+31% +$1.88M ﹤0.01% 2637
2017
Q3 		$6.54M Sell
64,274
-91,493
-59% -$8M ﹤0.01% 2689
2017
Q2 		$11.9M Buy
155,767
+103,341
+197% +$8.69M ﹤0.01% 2008
2017
Q1 		$4.52M Sell
52,426
-15,454
-23% -$1.11M ﹤0.01% 2954
2016
Q4 		$4.36M Buy
67,880
+4,474
+7% +$275K ﹤0.01% 3138
2016
Q3 		$4.1M Buy
63,406
+3,431
+6% +$193K ﹤0.01% 2865
2016
Q2 		$3.33M Buy
59,975
+5,857
+11% +$295K ﹤0.01% 2983
2016
Q1 		$2.26M Sell
54,118
-58,522
-52% -$2.72M ﹤0.01% 3249
2015
Q4 		$7.08M Buy
112,640
+31,019
+38% +$1.59M ﹤0.01% 2323
2015
Q3 		$3.32M Buy
81,621
+69,123
+553% +$3.98M ﹤0.01% 3021
2015
Q2 		$644K Buy
+12,498
New +$663K ﹤0.01% 4525

Other funds holding LKFT

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
DCM
DME Capital Management New York $3.19B AUM 23.22% 1-Year Est. Return
SBH
Segall Bryant & Hamill Chicago, Illinois $6.98B AUM 34.78% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley's LKFT Position: Q1 2026 in Review

Morgan Stanley reduced its Lakefront Biotherapeutics American Depositary Shares (LKFT) stake by 61% in Q1 2026, selling an estimated $1.38M and leaving 26,619 shares worth $799K. The position accounts for ﹤0.01% of the portfolio, ranked #5260.

Morgan Stanley first reported a position in LKFT in Q2 2015 and has held it in 44 quarters since. The position peaked at $23.7M in Q1 2020. 90 funds tracked by Wall St. Rank hold LKFT as of Q1 2026.

  • Morgan Stanley held 26,619 shares of Lakefront Biotherapeutics American Depositary Shares worth $799K as of Q1 2026.
  • Morgan Stanley sold 41,666 Lakefront Biotherapeutics American Depositary Shares shares in Q1 2026, an estimated $1.38M.
  • Lakefront Biotherapeutics American Depositary Shares made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #5260 holding.
  • Morgan Stanley first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q2 2015 and has held it in 44 quarters since.
  • Morgan Stanley's Lakefront Biotherapeutics American Depositary Shares position peaked at $23.7M in Q1 2020.
  • 90 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.